⏱ 11 min read

Dr. Hayes Q&A · No. 035
By Eleanor Hayes, M.D. · Hospitalist
Fatty liver is one of the most common findings on an abdominal scan in this country, and one of the most casually delivered. “A little fat in the liver. Lose some weight.” For many people, that is a fair summary. For some, it skips the one question that decides how serious fatty liver really is.
The Question
“An ultrasound I had for gallbladder pain said ‘hepatic steatosis.’ My doctor said it’s fatty liver, very common, try to lose some weight, and that was the end of it. I barely drink. Is this something I should actually worry about? And what is MASLD? I keep seeing it everywhere.”
— Name withheld
| The Basics | |
|---|---|
| Questioner | Male · 56 |
| Situation | Fat in the liver found by chance on an ultrasound done for gallbladder pain; told to lose weight, no further testing ordered |
| Symptoms | None from the liver; the gallbladder pain has settled |
| Existing conditions | Type 2 diabetes for six years; recent labs AST 39, ALT 48, platelets 168 |
| Supplements / medications | Metformin; stopped his statin last year after reading that statins are “hard on the liver” |
The Short Answer
Fat in the liver is common and, on its own, usually not dangerous. What matters is whether it has begun to scar the liver, and that can be estimated from ordinary blood tests with a simple calculation called FIB-4. For this reader, two lines in his table stand out. Type 2 diabetes raises the odds of scarring, so he needs that estimate. And the statin he stopped is one he very likely needs more, not less.
How Serious Fatty Liver Is, and What Decides It
A new name. In 2023, the major liver societies replaced the old term NAFLD with MASLD, short for metabolic dysfunction-associated steatotic liver disease. The more serious inflamed form, once called NASH, is now MASH. The point of the change was to name the cause: fat in the liver along with at least one heart and metabolic risk factor, such as extra weight or a large waist, high blood sugar, high blood pressure, high triglycerides, or low HDL. People who also drink a moderate amount fall into a related category called MetALD. (AASLD on the new fatty liver nomenclature)
How common it is. Estimates in the United States run from about 10 percent to more than 40 percent of adults, depending on how the liver fat is measured. One analysis of national survey data projected roughly 73 million American adults with MASLD. (AASLD meeting abstract on MASLD and fibrosis) It is common enough that “very common” is an accurate thing for a doctor to say. It is not the same as “nothing to check.”
Fat is not the danger. Scarring is. Fatty liver runs along a spectrum. It starts with fat alone. In some people the fat inflames the liver, which is MASH. Ongoing inflammation lays down scar tissue, called fibrosis. Heavy scarring becomes cirrhosis, which can bring fluid in the belly, bleeding, confusion, and liver cancer. Most people with fatty liver never move past the first stage. The amount of scarring is what best predicts who will.
The number most people never get: FIB-4. FIB-4 combines four things already on most routine panels: age, two liver enzymes (AST and ALT), and the platelet count. A score under 1.3 suggests a low risk of significant scarring. A score of 1.3 or higher calls for a second test, usually a FibroScan, an ultrasound-based measure of liver stiffness, or a blood test called ELF. (AASLD clinical pearls)
| FIB-4 Score | What It Suggests | Usual Next Step |
|---|---|---|
| Under 1.3 | Low risk of significant scarring | Work on the risk factors; repeat the estimate over time |
| 1.3 to 2.67 | Uncertain; scarring possible | A second test, such as a FibroScan or ELF |
| Above 2.67 | Advanced scarring more likely | Referral to a liver specialist |
FIB-4 is a screening tool, not a verdict. It is less reliable in people under 35 and over 65, and in someone who is acutely ill. The same national analysis above estimated that most American adults with significant scarring would still score under 1.3. A low score is reassuring, not a guarantee, especially in someone with diabetes.
For most people, the heart is the bigger threat. Fat in the liver travels with the same things that clog arteries. The American Heart Association notes that abdominal fat often leads to fat in the liver, which adds to the risk of heart disease. (AHA statement on abdominal obesity) That is why statins matter here. They are considered safe in people with fatty liver and are used whenever heart risk calls for them. A mild rise in liver enzymes is not, by itself, a reason to stop one.
Weight loss works, and the amount matters. In a well-known study, 293 people with biopsy-proven MASH followed a year of diet and exercise changes and had a second biopsy. Among those who lost 10 percent or more of their weight, 90 percent saw the inflammation resolve and 45 percent saw scarring improve. Among those who lost 7 to 10 percent, the inflammation resolved in 64 percent. (weight loss and MASH, Gastroenterology 2015) Few treatments in medicine show a dose response that clear. Even 5 percent helps. Ten percent is the number that reaches the scar.
Medicines now exist for the scarred liver. In March 2024, the FDA approved resmetirom, the first drug for MASH with scarring. In August 2025 it granted accelerated approval to semaglutide, sold as Wegovy, for adults with MASH and moderate to advanced scarring who do not have cirrhosis. (FDA announcement on semaglutide for MASH) Both are meant for people with confirmed scarring, not for fat alone, and both work alongside weight loss rather than in place of it. What happens when a drug like semaglutide is stopped is covered in the Q&A on stopping GLP-1 drugs.
Back to the table. Now his numbers. FIB-4 is age times AST, divided by platelets times the square root of ALT. For him that is 56 times 39, which is 2,184, divided by 168 times about 6.93, which is about 1,164. His score is about 1.9. That is not low risk. It sits in the uncertain middle, and by current guidance it calls for a second test, not a shrug. Six years of type 2 diabetes makes that test more pressing, because diabetes is one of the strongest drivers of scarring. An ALT of 48 is a little above where many labs set their upper limit, a topic covered in the Q&A on liver enzymes, though a normal ALT would not have ruled scarring out either. And the statin. For a man with diabetes and fatty liver, his heart is the organ most likely to cause trouble first. Stopping the statin to protect his liver traded a small, mostly theoretical worry for a larger, well-measured one.
Work Out Your Own FIB-4
FIB-4 = (Age × AST) ÷ (Platelets × √ALT)
· Find the numbers on a recent blood panel: AST and ALT (in U/L) and platelets (in thousands per microliter, such as 168).
· Multiply your age by your AST.
· Take the square root of your ALT and multiply it by your platelet count.
· Divide the first number by the second.
· Bring the result to your doctor, along with any scan that mentioned fat in the liver. The score is meant for adults roughly 35 to 65 and is not reliable during an acute illness.
What I See in the Hospital
The fatty livers I see in the hospital are the ones nobody followed. By the time someone is admitted, the word on the chart is cirrhosis, and the problem in front of me is fluid in the belly, bleeding, or confusion. Looking back through those records, the trail often starts years earlier: a scan that mentioned fat, an enzyme a little high, diabetes on the problem list, and no one checking for scarring in between. The Hospital 366 case on MASLD and cirrhosis follows one version of that road.
The other pattern is the medication quietly dropped. A statin or a diabetes drug gets stopped because of a worry about the liver, and the liver was never the organ in danger.
Plain-Language Reference
| Term | What It Means in Plain Language |
|---|---|
| Hepatic steatosis | The medical term for fatty liver. |
| MASLD | Fatty liver linked to weight, blood sugar, blood pressure, or blood fats; formerly NAFLD. |
| MASH | Fatty liver with inflammation and liver cell injury; formerly NASH. |
| Fibrosis | Scar tissue in the liver, graded by how much there is. |
| Cirrhosis | Heavy scarring that changes how the liver works. |
| FIB-4 | A score from age, AST, ALT, and platelets that estimates scarring risk. |
| FibroScan | An ultrasound-based test that measures how stiff the liver is. |
What to Actually Do
· If a scan mentioned fatty liver, ask your doctor for your FIB-4 score, or work it out from your last panel.
· If the score is 1.3 or higher, or you have type 2 diabetes, ask whether a FibroScan or similar test makes sense.
· Do not stop a statin or diabetes medicine because of a liver worry without talking to the prescriber first.
· Aim for a 7 to 10 percent weight loss over a year. That is the range where the liver itself measurably heals.
· Keep alcohol low. Even modest drinking adds to fat-related liver damage.
· Recheck the estimate every year or two. A single low score is not lifelong clearance.
More From Dr. Hayes Q&A
· Q&A 014: What Do Liver Enzymes (ALT/AST) Actually Measure?
· Q&A 034: Is Belly Fat Different From Other Fat?
· Q&A 033: What Happens When You Stop a GLP-1 Drug?
· Hospital 366: MASLD, Cirrhosis, and Anemia
Check Your Numbers (ManClub Health Tools)
· Blood Work Decoder (read your AST, ALT, platelets, and other lab numbers in plain language)
· Heart Age Calculator (because with fatty liver, the heart usually carries the larger risk)
This article is for general information only and does not constitute medical advice, diagnosis, or treatment. Reading it creates no provider-patient relationship. The reader’s situation is a composite and does not represent any specific person. FIB-4 is a screening estimate and cannot diagnose or rule out liver scarring on its own. Drug approvals described here reflect FDA actions as of publication. Do not start, stop, or change any medication without talking to the clinician who prescribed it. If you notice yellowing of the skin or eyes, a swelling belly, vomiting blood, black stools, or new confusion, seek emergency care.
Take care of yourself. Nobody else will do it for you.
— Eleanor Hayes, M.D.

Eleanor Hayes, M.D., is a practicing, board-certified Family Medicine physician with extensive hospital-based clinical experience across multiple U.S. regions. At ManClub she writes data-driven pieces on public health, healthcare systems, and population health trends, and serves as the site’s independent medical reviewer. “Eleanor Hayes” is a professional pen name used to protect patient privacy; all credentials are verified internally. She is the author of “Reading the Table” (2026). Full bio and credentials: Dr.Hayes-reviewer. Contact: [email protected].